Oultram Jackson M J, Pegler Joseph L, Bowser Timothy A, Ney Luke J, Eamens Andrew L, Grof Christopher P L
Centre for Plant Science, University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.
CannaPacific Pty Ltd., 109 Ocean Street, Dudley, NSW 2290, Australia.
Biomedicines. 2021 Feb 26;9(3):234. doi: 10.3390/biomedicines9030234.
() is one of the world's most well-known, yet maligned plant species. However, significant recent research is starting to unveil the potential of to produce secondary compounds that may offer a suite of medical benefits, elevating this unique plant species from its illicit narcotic status into a genuine biopharmaceutical. This review summarises the lengthy history of and details the molecular pathways that underpin the production of key secondary metabolites that may confer medical efficacy. We also provide an up-to-date summary of the molecular targets and potential of the relatively unknown minor compounds offered by the plant. Furthermore, we detail the recent advances in plant science, as well as synthetic biology, and the pharmacology surrounding Given the relative infancy of research, we go on to highlight the parallels to previous research conducted in another medically relevant and versatile plant, (opium poppy), as an indicator of the possible future direction of plant biology. Overall, this review highlights the future directions of cannabis research outside of the medical biology aspects of its well-characterised constituents and explores additional avenues for the potential improvement of the medical potential of the plant.
()是世界上最著名但也备受诋毁的植物物种之一。然而,最近的重要研究开始揭示其产生次生化合物的潜力,这些次生化合物可能具有一系列医疗益处,从而将这种独特的植物物种从非法麻醉品地位提升为真正的生物制药原料。本综述总结了()的悠久历史,并详细阐述了支撑可能具有医疗功效的关键次生代谢产物产生的分子途径。我们还提供了关于()植物提供的相对不为人知的次要化合物的分子靶点和潜力的最新总结。此外,我们详细介绍了植物科学以及合成生物学方面的最新进展,以及围绕()的药理学。鉴于()研究尚处于起步阶段,我们接着强调与另一种具有医学相关性且用途广泛的植物(罂粟)先前研究的相似之处,以此作为()植物生物学未来可能发展方向的指标。总体而言,本综述突出了大麻研究在其特征明确的成分的医学生物学方面之外的未来方向,并探索了进一步提升()植物医疗潜力的其他途径。